Abiopharma

🔍 Brophy Michael Burkes (Executive)

Company: Natera, Inc. (NTRA)

Report Date: 2026-04-27

Detailed Transactions and Holdings:

• Sold 771 shares of Common Stock at $203.75 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 62,583.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,222 shares of Common Stock at $204.39 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 61,361.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 300 shares of Common Stock at $190.115 per share (Direct)
  Date: 2026-04-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 61,061.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 500 shares of Common Stock at $192.1286 per share (Direct)
  Date: 2026-04-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 60,561.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 1,000 shares of Common Stock at $193.779 per share (Direct)
  Date: 2026-04-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 59,561.00 | transaction_form_type: 4 | Footnotes: F3, F6
• Sold 1,070 shares of Common Stock at $194.822 per share (Direct)
  Date: 2026-04-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 58,491.00 | transaction_form_type: 4 | Footnotes: F3, F7
• Sold 200 shares of Common Stock at $197.26 per share (Direct)
  Date: 2026-04-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 58,291.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024.
• F2: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023.
• F3: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as amended on September 5, 2025.
• F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.08 to $190.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.83 to $192.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.26 to $194.12 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.45 to $195.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.